Table 1.
Baseline patient characteristics
| Trial/treatment | n | Age (years), mean | White race, n (%) | Body weight (kg), mean | ECOG PS ≤1, n (%) | ECOG PS 2, n (%) | Post-menopausal, n (%) |
|---|---|---|---|---|---|---|---|
| Visceral dominant metastasis | |||||||
| CA012 | |||||||
| nab-P 260 mg/m2 q3w | 74 | 52.2 | 70 (95) | 72.4 | 68 (92) | 6 (8) | 52 (70) |
| P 175 mg/m2 q3w | 64 | 53.0 | 60 (94) | 71.5 | 63 (98) | 1 (2) | 45 (70) |
| CA024 | |||||||
| nab-P 300 mg/m2 q3w | 61 | 51.6 | 59 (97) | 73.2 | 55 (90) | 6 (10) | 39 (64) |
| nab-P 100 mg/m2 qw 3/4 | 60 | 55.6 | 59 (98) | 71.8 | 56 (93) | 4 (7) | 50 (83) |
| nab-P 150 mg/m2 qw 3/4 | 59 | 53.8 | 59 (100) | 76.1 | 55 (93) | 4 (7) | 45 (76) |
| Doc 100 mg/m2 q3w | 67 | 56.2 | 67 (100) | 75.9 | 65 (97) | 2 (3) | 57 (85) |
| Short DFI | |||||||
| CA012 | |||||||
| nab-P 260 mg/m2 q3w | 42 | 50.8 | 42 (100) | 72.4 | 39 (93) | 3 (7) | 31 (74) |
| P 175 mg/m2 q3w | 30 | 52.3 | 30 (100) | 70.0 | 30 (100) | 0 | 21 (70) |
| CA024 | |||||||
| nab-P 300 mg/m2 q3w | 20 | 49.5 | 20 (100) | 73.2 | 18 (90) | 2 (10) | 13 (65) |
| nab-P 100 mg/m2 qw 3/4 | 21 | 51.4 | 21 (100) | 75.7 | 21 (100) | 0 | 17 (81) |
| nab-P 150 mg/m2 qw 3/4 | 14 | 52.2 | 14 (100) | 80.1 | 12 (86) | 2 (14) | 9 (64) |
| Doc 100 mg/m2 q3w | 19 | 51.5 | 19 (100) | 84.5 | 19 (100) | 0 | 14 (74) |
DFI disease-free interval, nab-P nab-paclitaxel, Doc docetaxel, ECOG PS Eastern Cooperative Oncology Group performance status, P paclitaxel, q3w every 3 weeks, qw 3/4 the first 3 of 4 weeks